Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

H.C. Wainwright downgraded Tempest Therapeutics (TPST) to Neutral from Buy without a price target after the company announced it is seeking to ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

Rallybio (RLYB – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Mitchell Kapoor today. The company’s ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy recommendation. As of April 2, 2025, the average one-year price target ...

Voyager Therapeutics VYGR during the recent three months, expressing a mix of bullish and bearish perspectives. The table ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...